Company Performance Metrics
- John Price: President & Chief Executive Officer
- William Connolly: Executive Vice President
Innovative and proven technologies, Greffex is continuing to invent the future of vaccines and genetic medicine. GREVAX™ Universal Platform in conjunction with Greffex’s proprietary engineered veto strategy allows the development of a new generation of immune evading gene therapy vectors and novel approaches to immune suppression in organ
transplantation. The company founded on the principles of creating innovative therapies to protect and heal mankind while keeping their focus on the value propositions available to them by being novel, successful and progressive.